House investigators said Biogen set an “unjustifiably high” initial price of $56,000 a year for Aduhelm, and it had “atypical collaboration” with the FDA. Read More
Alzheimer’s drug approval by FDA ‘rife with irregularities,’ Congress finds after 18-month investigation
